Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)
CUSIP: 28036F105
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 109,183,673
- Total 13F shares
- 5,828,831
- Share change
- -445,486
- Total reported value
- $183,654,723
- Price per share
- $31.50
- Number of holders
- 58
- Value change
- -$13,861,048
- Number of buys
- 28
- Number of sells
- 14
Quarterly Holders Quick Answers
What is CUSIP 28036F105?
CUSIP 28036F105 identifies EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 28036F105:
Top shareholders of EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
|
Company · Director, 10%+ Owner |
14%
from 13D/G
|
15,518,492
|
$385,091,379 | — | 31 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
|
Company |
9.9%
from 13D/G
|
10,428,437
|
$258,781,664 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.5%
from 13D/G
|
6,630,576
|
$164,537,741 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
13D/G
|
Company |
6.9%
from 13D/G
|
6,575,940
|
$163,181,951 | — | 31 Dec 2025 | |
| Paradigm Biocapital Advisors LP |
13F
13D/G
|
Company |
6.2%
from 13D/G
|
6,541,210
|
$162,320,126 | — | 31 Dec 2025 | |
| Novo Holdings A/S |
13F
3/4/5
|
Company · 10%+ Owner |
4.9%
|
5,350,000
|
$132,760,250 | — | 31 Dec 2025 | |
| BRAIDWELL LP |
13F
|
Company |
4.8%
|
5,210,831
|
$129,306,771 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.5%
|
4,871,624
|
$120,889,349 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
|
Company |
4.7%
from 13D/G
|
4,566,850
|
$113,326,384 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
4.1%
|
4,529,990
|
$112,411,702 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
|
Company |
4.4%
from 13D/G
|
4,457,974
|
$110,624,625 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.8%
|
4,191,193
|
$104,004,458 | — | 31 Dec 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
3%
|
3,285,000
|
$81,517,275 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.7%
|
2,910,881
|
$72,233,511 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
1.9%
|
2,117,073
|
$52,535,166 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,746,222
|
$43,340,399 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
1,717,343
|
$42,615,867 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.5%
|
1,655,256
|
$41,075,178 | — | 31 Dec 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
1.4%
|
1,573,701
|
$39,051,392 | — | 31 Dec 2025 | |
| Bellevue Group AG |
13F
|
Company |
1.4%
|
1,528,518
|
$37,930,174 | — | 31 Dec 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.4%
|
1,500,000
|
$37,222,500 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.4%
|
1,474,797
|
$36,597,088 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.1%
|
1,213,657
|
$30,114,975 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
1.1%
|
1,186,467
|
$29,442,210 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.95%
|
1,036,170
|
$25,712,559 | — | 31 Dec 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.83%
|
910,000
|
$22,581,650 | — | 31 Dec 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.75%
|
821,940
|
$20,396,441 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.7%
|
765,694
|
$19,000,697 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
0.69%
|
751,355
|
$18,644,874 | — | 31 Dec 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.68%
|
746,562
|
$18,525,936 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.66%
|
718,372
|
$17,826,402 | — | 31 Dec 2025 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
0.64%
|
704,077
|
$17,471,671 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.63%
|
692,955
|
$17,195,678 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.62%
|
681,921
|
$16,925,279 | — | 31 Dec 2025 | |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND |
13F
|
Company |
0.59%
|
640,400
|
$15,891,526 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.56%
|
611,384
|
$15,171,494 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.52%
|
568,310
|
$14,102,613 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
559,649
|
$13,887,690 | — | 31 Dec 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.46%
|
501,214
|
$12,438,155 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.46%
|
500,000
|
$12,407,500 | — | 31 Dec 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.4%
|
437,819
|
$10,864,478 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.39%
|
427,690
|
$10,613,127 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.36%
|
394,695
|
$9,794,356 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.34%
|
372,738
|
$9,249,495 | — | 31 Dec 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.33%
|
360,876
|
$8,955,138 | — | 31 Dec 2025 | |
| Peter A. Thompson |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
473,792
mixed-class rows
|
$8,933,533 | — | 16 Jun 2025 | |
| Squadron Capital Management LLC |
13F
|
Company |
0.32%
|
350,000
|
$8,685,250 | — | 31 Dec 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.31%
|
337,340
|
$8,371,092 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.27%
|
296,208
|
$7,350,402 | — | 31 Dec 2025 | |
| Universal- Beteiligungs- und Servicegesellschaft mbH |
13F
|
Individual |
0.25%
|
271,385
|
$6,734,419 | — | 31 Dec 2025 |
Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) as of Q1 2026
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.